Edesa Biotech reports Q3 net loss of $5.4M; advances EB06 vitiligo Phase 2

Edesa Biotech, Inc.

Q3 net loss $5.4M ($0.60/share) vs $1.7M ($0.25) year ago; nine-month loss $11.9M ($1.40) vs $5.0M ($0.95).
R&D expenses rose $3.1M to $4.0M in Q3 on EB06 manufacturing and prep; total opex $5.5M vs $1.9M.
Cash and equivalents $10.3M, working capital $6.9M at June 30, 2026.
EB06 Phase 2 vitiligo study prep complete; first sites activating, recruitment to start in coming weeks in Canada.
Paridiprubart exploratory data in ARDS with AKI showed significant mortality reduction and improved MAKE30 endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.